Newron Pharmaceuticals SpA (NWRN) - Total Assets

Latest as of December 2025: CHF40.02 Million CHF ≈ $50.60 Million USD

Based on the latest financial reports, Newron Pharmaceuticals SpA (NWRN) holds total assets worth CHF40.02 Million CHF (≈ $50.60 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Newron Pharmaceuticals SpA (NWRN) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Newron Pharmaceuticals SpA - Total Assets Trend (2005–2025)

This chart illustrates how Newron Pharmaceuticals SpA's total assets have evolved over time, based on quarterly financial data. Explore NWRN long-term investment intensity to see how much of total assets are deployed in long-term investments.

Newron Pharmaceuticals SpA - Asset Composition Analysis

Current Asset Composition (December 2025)

Newron Pharmaceuticals SpA's total assets of CHF40.02 Million consist of 95.1% current assets and 4.9% non-current assets.

Asset Category	Amount (CHF)	% of Total Assets
Cash & Equivalents	CHF0.00	30.4%
Accounts Receivable	CHF6.16 Million	15.4%
Inventory	CHF0.00	0.0%
Property, Plant & Equipment	CHF736.00K	1.8%
Intangible Assets	CHF999.22	0.0%
Goodwill	CHF0.00	0.0%

Asset Composition Trend (2005–2025)

This chart illustrates how Newron Pharmaceuticals SpA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see NWRN stock market capitalisation.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Newron Pharmaceuticals SpA's current assets represent 95.1% of total assets in 2025, an increase from 90.6% in 2005.
Cash Position: Cash and equivalents constituted 30.4% of total assets in 2025, down from 74.3% in 2005.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2005.
Asset Diversification: The largest asset category is accounts receivable at 15.4% of total assets.

Newron Pharmaceuticals SpA Competitors by Total Assets

Key competitors of Newron Pharmaceuticals SpA based on total assets are shown below.

Company	Country	Total Assets
Biomarin Pharmaceutical Inc NASDAQ:BMRN	USA	$8.59 Billion
Cyclacel Pharmaceuticals Inc NASDAQ:CYCC	USA	$4.40K
Krystal Biotech Inc NASDAQ:KRYS	USA	$1.40 Billion
Verona Pharma PLC ADR NASDAQ:VRNA	USA	$572.87 Million
Centessa Pharmaceuticals PLC ADR NASDAQ:CNTA	USA	$641.76 Million
Beijing Tiantan Biological Products Corp Ltd SHG:600161	China	CN¥16.55 Billion
Hebei Changshan Biochem Pharma SHE:300255	China	CN¥4.66 Billion
BB Biotech AG SW:BION	Switzerland	CHF2.64 Billion

Newron Pharmaceuticals SpA - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	0.76	2.60	5.50
Quick Ratio	0.76	2.60	5.50
Cash Ratio	0.00	0.00	0.00
Working Capital	CHF-12.04 Million	CHF37.60 Million	CHF30.98 Million

Newron Pharmaceuticals SpA - Advanced Valuation Insights

This section examines the relationship between Newron Pharmaceuticals SpA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	200.34
Latest Market Cap to Assets Ratio	7.42
Asset Growth Rate (YoY)	-37.4%
Total Assets	CHF40.02 Million
Market Capitalization	$297.11 Million USD

Valuation Analysis

Premium Asset Valuation: The market values Newron Pharmaceuticals SpA's assets at a significant premium (7.42x), suggesting investors see substantial growth potential or unique competitive advantages.

Significant Asset Reduction: Newron Pharmaceuticals SpA's assets decreased by 37.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for Newron Pharmaceuticals SpA (2005–2025)

The table below shows the annual total assets of Newron Pharmaceuticals SpA from 2005 to 2025.

Year	Total Assets	Change
2025-12-31	CHF40.02 Million ≈ $50.60 Million	-37.37%
2024-12-31	CHF63.91 Million ≈ $80.80 Million	+147.07%
2023-12-31	CHF25.87 Million ≈ $32.70 Million	-30.46%
2022-12-31	CHF37.20 Million ≈ $47.02 Million	-26.33%
2021-12-31	CHF50.49 Million ≈ $63.83 Million	-1.39%
2020-12-31	CHF51.20 Million ≈ $64.73 Million	-15.08%
2019-12-31	CHF60.29 Million ≈ $76.22 Million	+0.48%
2018-12-31	CHF60.00 Million ≈ $75.85 Million	-17.84%
2017-12-31	CHF73.02 Million ≈ $92.32 Million	+29.04%
2016-12-31	CHF56.59 Million ≈ $71.55 Million	+27.51%
2015-12-31	CHF44.38 Million ≈ $56.11 Million	+19.71%
2014-12-31	CHF37.07 Million ≈ $46.87 Million	+17.26%
2013-12-31	CHF31.62 Million ≈ $39.97 Million	-29.18%
2012-12-31	CHF44.65 Million ≈ $56.45 Million	+229.11%
2011-12-31	CHF13.57 Million ≈ $17.15 Million	-29.09%
2010-12-31	CHF19.13 Million ≈ $24.19 Million	-54.10%
2009-12-31	CHF41.68 Million ≈ $52.69 Million	-31.16%
2008-12-31	CHF60.54 Million ≈ $76.54 Million	-13.97%
2007-12-31	CHF70.37 Million ≈ $88.96 Million	-18.33%
2006-12-31	CHF86.16 Million ≈ $108.93 Million	+266.67%
2005-12-31	CHF23.50 Million ≈ $29.71 Million	--

About Newron Pharmaceuticals SpA

SW:NWRN Switzerland Biotechnology

Market Cap

$316.70 Million

CHF250.50 Million CHF

Market Cap Rank

#14986 Global

#155 in Switzerland

Share Price

CHF12.04

Change (1 day)

+0.17%

52-Week Range

CHF6.66 - CHF30.40

All Time High

CHF30.40